Study to Evaluate the Efficacy and Safety of AZD4831 in Participants with Heart Failure with Left Ventricular Ejection Fraction > 40% - ENDEAVOR

Study identifier:D6580C00010

ClinicalTrials.gov identifier:NCT04986202

EudraCT identifier:2020-005844-47

CTIS identifier:N/A

Recruitment Complete

Official Title

A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants with Heart Failure with Left Ventricular Ejection Fraction > 40%

Medical condition

Heart Failure with preserved Ejection Fraction

Phase

Phase 2/3

Healthy volunteers

No

Study drug

AZD4831

Sex

All

Actual Enrollment

711

Study type

Interventional

Age

40 Years - 85 Years

Date

Study Start Date: 30 Jun 2021
Estimated Primary Completion Date: 02 Apr 2024
Estimated Study Completion Date: 02 Apr 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria